Article
Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.
Vaccine - 12 Jan 2006
Kirkpatrick B D, McKenzie Robin, O'Neill J Patrick, Larsson Catherine J, Bourgeois A Louis, Shimko Janet, Bentley Matthew, Makin Jill, Chatfield Steve, Hindle Zoë, Fidler Christine, Robinson Brad E, Ventrone Cassandra H, Bansal Nivedita, Carpenter Colleen M, Kutzko Deborah, Hamlet Sandra, LaPointe Casey, Taylor David N
Abstract excerpt
Salmonella enterica serovar Typhi strains with mutations in the Salmonella pathogenicity island-2 (SPI-2) may represent an effective strategy for human vaccine development, and a vectoring system for heterologous antigens. S. Typhi (Ty2 aroC-ssaV-) M01ZH09 is an attenuated, live, oral typhoid vaccine harboring defined deletion mutations in ssaV, which encodes an integral component in the SPI-2 type III secretion...
Topics
- Administration, Oral
- Adult
- Double-Blind Method
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Male
- Middle Aged
- Mutation